Boston

3 Lessons From NuTonomy & Lyft's Self-Driving Car Rides in Boston

One year ago   |   By Xconomy

One of the biggest potential pitfalls for developers of autonomous vehicles is psychological: Will most people trust the cars enough to ride in them? It might not be easy to win people over, but it's possible-if a Boston startup's recent tests are any indication. On Tuesday, NuTonomy co-founder and president Karl Iagnemma shared early reactions from people who have ridden in cars controlled by his company's software. “The feedback has been really interesting, and I would say overwhelmingly positive,” Iagnemma said at a press briefing, during which NuTonomy and its parent company, Aptiv...
Read more ...

 


Search by Tags

   Boston      Boston blog main      Boston top stories      National blog main      National top stories      San Francisco blog main      Aptiv      Autonomous vehicles      Delphi      Delphi Automotive      Driverless      Driverless cars      Karl Iagnemma      Lyft      NuTonomy      RoboticsAI      Self-driving      Self-Driving Cars      Software      Startups      Tech      Xperience  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

An Entrepreneur's Quest to Make Seattle a Genome Sciences Hub

An Entrepreneur's Quest to Make Seattle a Genome Sciences Hub

Ivan Liachko turned postdoctoral research at the University of Washington into a company whose genomics tools are now found in laboratories researching human, animal, and plant... Read more ...

Flagship's Omega Aims to Take Epigenetic Drugs a Step Further

Flagship's Omega Aims to Take Epigenetic Drugs a Step Further

A biotech startup called Omega Therapeutics debuts this morning touting a new approach to developing medicines based on epigenetics, a field of research that has tantalized... Read more ...

Topping the Medical Charts

San Diego Magazine “Physicians of Exceptional Excellence” survey, an annual opportunity for doctors across the region to vote for much-admired colleagues. ]]> ... Read more ...

Capturing extreme close-ups of cellular gene expression

Scientists studying genetic transcription are gaining new insights into a process that is fundamental to all life. Transcription is the first step in gene expression, the... Read more ...

Strip Steak: Bacterial Enzyme Removes Inflammation-Causing Meat Carbohydrates

Read more ...

Perturbed Genes Regulating White Blood Cells Linked to Autism Genetics and...

Read more ...

Ionis subsidiary Akcea ousts leadership team

Biotech veteran Damien McDevitt takes over as interim CEO... Read more ...

Enough with the Insanity. We Need to Fix Cybersecurity Now

The year 2019 has been another dreadful period for cyberattacks. The most notorious lowlights include: -More than 40 municipalities , including Baltimore, Albany and 22 cities... Read more ...

Gene therapy startup Passage Bio nabs Janssen neuro lead as CMO

Mere weeks after getting off a major $110 million series B round, well-funded Passage Bio has grabbed a new C-suite member on top of its cash haul. Read more ...

Clovis strikes 3B deal to move into radiopharmaceuticals

Clovis Oncology has paid $12 million for rights to FAP-targeted radiopharmaceuticals in development at 3B Pharmaceuticals. The deal gives Clovis the ex-Europe rights to a... Read more ...